Vivos Therapeutics (NASDAQ: VVOS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.45) by 15.56 percent. This is a 15.56 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $5.141 million which beat the analyst consensus estimate of $4.225 million by 21.68 percent. This is a 70.46 percent increase over sales of $3.016 million the same period last year.